Alnylam Initiates Phase I Clinical Study of RNAi Therapeutic for the Treatment of Respiratory Syncytial Virus (RSV) Infection
Alnylam Becomes a Clinical-Stage Company with the Industry's First Trial of an RNAi Therapeutic for Viral Infectious Disease
09-Dec-2005 -
Alnylam Pharmaceuticals, Inc. announced that it has initiated a Phase I study in Europe to evaluate the human safety and pharmacology of ALN-RSV01, an RNAi therapeutic, in healthy volunteers. Additionally, the company's investigational new drug (IND) application to conduct a separate Phase I ...
Alnylam
clinical trials
food
+5